Research Objectives

Dr Vinogradova aims to identify risks of developing serious side effects associated with different commonly prescribed menopausal hormone therapy (MHT) treatments.

References


Collaborators

- Carol Coupland (Nottingham)
- Tom Dening (Nottingham)
- Julia Hippisley-Cox (Oxford)
- Michael Moore (Southampton)
- Lauren Taylor (Nottingham)

Funding

- MHT/VTE: Unfunded
- MHT/Cancer: National Institute for Health Research Project Ref 848619; Cancer Research UK (Grant No C5255/A18085)
- MHT/Dementia: National Institute for Health Research FR19 No 480 & No 3372)

Address

Division of Primary Care, Tower Building
University Park
Nottingham, NG7 2RD, UK

Bio

Dr Vinogradova is a mathematician–statistician/epidemiologist by training. She is currently a Senior Research Fellow at the Medical School of University of Nottingham, UK. Her research focuses on drug safety, using primary care data to determine outcomes for rare or slowly developing problems within the general population in ‘real world’ environments.

Personal Response

How are you planning to advance your research?

I plan to undertake more MHT studies and extend my work involving research on women’s health.
Menopausal hormone therapy (MHT) is used to ease severe symptoms associated with the menopause and can be administered in tablet, patch, gel, or implant form. However, previous research has suggested treatments may have serious side effects, including increased risks of developing blood clots, breast cancer, and dementia.

Dr Yana Vinogradova of Nottingham University Medical School, UK, supported by UK researchers from Nottingham, Oxford and Southampton, has conducted large-scale independent studies into the levels of risk associated with different MHT treatments to improve information available to patients and their clinicians.

Fluctuating hormone levels in menopausal women can cause a variety of unpleasant symptoms such as hot flushes, headaches, sore breasts, vaginal dryness, insomnia, anxiety, memory impairment, mood swings, and depression. Anxiety can be particularly severe and have a significantly negative impact on their quality of life.

**PROVIDING RELIEF**

MHT treatment involves the use of one or more types of hormonal drugs. Oestrogen-only therapy is given to women who have undergone procedures involving removal of their ovaries, uterus or womb and is delivered in the form of an oral pill, a patch, a gel, or a topical or vaginal cream. For other women, a combined therapy will be prescribed, where a progestin is added to the oestrogen to protect the uterus and reduce the risk of endometrial cancer. This treatment will be delivered either as a pill or an intrauterine device (IUD).

**SERIOUS SIDE EFFECTS**

All drug treatments have potential side effects. In the case of MHT, these range from mild to severe, depending on the patient. Serious side effects found in studies have included increased risks of venous thromboembolism (VTE), breast cancer, and dementia.

Two large early studies – the Women’s Health Initiative trial (WHI), published in 2002, and the Million Women observational study, published in 2003 – first highlighted associated risks with VTE and breast cancer. This resulted in a significant drop in the uptake of MHT, which persisted, and in 2015 the National Institute of Health and Clinical Excellence (NICE) issued recommendations to increase the use of hormonal treatments, calling for more detailed research evidence on serious side effects.

This sparked significant research efforts, but the requirement for evidence on specific treatment components and regimens is challenging because serious side effects are rare and/or develop slowly. Trials are difficult or impossible because of costs, and observational studies also need to access a broad range of data over many years. Most studies have been limited either to a few specific treatments, don’t have a sufficiently large sample size to provide robust estimates at the level of detail required, or have suffered from a range of design weaknesses.

**NEW RESEARCH**

To fill the knowledge gaps and reduce uncertainty, Dr Yana Vinogradova of Nottingham University in the UK has undertaken a series of very large observational studies into serious side effects of MHT. For each, she has used a methodology, pioneered by her, of combining results from identical observational studies on two of the largest primary care databases in the UK (QResearch and CPRD). These contain patient records from the UK’s National Health Service’s (NHS) general practices and have links to hospital (secondary care) and mortality records. Together, they constitute a rich data source of patient records over a long period. Patient information include diagnoses, prescription details, and patient-related records on many factors associated with the development of specific medical problems, which may be potential confounders.

This has created sufficient power to provide accurate and robust estimates of the additional risks of developing a serious side effect for any of the MHT treatments prescribed by the NHS. All the studies are independent, original research with consistent design, using sophisticated data-management techniques and methodology, and with estimates adjusted for all available confounders.
MHT AND VTE
The first paper, investigating MHT and the risk of developing VTE, was published in 2019. The study included information for all women between the ages of 40 and 79 if registered with a practice between 1998 and 2017. There were 80,396 women with a diagnosis of VTE (cases), and each was matched with up to five women of the same age, from the same practice and with no diagnosis of VTE at the date of the case diagnosis (controls). The analysis compared the participant’s use of MHT before the diagnosis date. Because risk of VTE declines after discontinuation of MHT, the analysis included only exposures in the last 90 days (7.2% of cases and 5.3% of controls).

The majority of women on MHT (85% of cases and 78% of controls) were prescribed oestrogen-only or combined, compared to no exposure, to be raised by 43% (equivalent to extra nine cases per 10,000 women years). For oral therapy, the type of oestrogen used in the treatment was found to be important. Estradiol, (here ethinyl estradiol), a synthetic derivative of natural oestrogen, was shown to present a lower additional risk than conjugated equine oestrogen or any of the combined treatments. Within the combined treatments, estradiol with dydrogesterone displayed the lowest risk and conjugated equine oestrogen with medroxyprogesterone acetate (the combination used in the American WHI study) was associated with the highest risk.

Notably, transdermal treatments, whether oestrogen-only or combined, were not associated with any elevated risk of VTE. Such transdermal treatments were, however, not commonly prescribed, with oral preparations being widely favoured.

MHT AND BREAST CANCER
In 2020, a second paper investigating the link between breast cancer and MHT was published. This took the same approach as the previous paper, matching 98,611 women between the ages of 50 and 79 with a diagnosis of breast cancer (cases) to up to five controls. This left 34% of participants and 37% controls with prescriptions for MHT before the relevant breast cancer diagnosis date.

Compared to women who had never used MHT, oestrogen-only treatments were found to be associated with only slightly increased risks, but combined oestrogen–progestin treatments were linked to higher risks. For oestrogen-only treatments, there was no difference in risks between the oestrogs studied, but for combined treatments there were different levels of risk for different combinations of hormones. The highest risk was found for conjugated equine oestrogen with medroxyprogesterone and the lowest risk was found for estradiol–dydrogesterone.

The additional risks of breast cancer decline after discontinuation of treatment, so, for women who had used a combined MHT in the last five years (recent use), overall risk was increased by an average of 5% (equivalent to between nine and 16 extra cases per 10,000 women years, depending on duration of use and age group) but, for women who had stopped five years ago or more, overall increased risk was only an average of 4%. For oestrogen-only treatments, the overall risk was increased by an average 12% for recent use, while no risk was found for those who had stopped five or more years before. The longer the participant used MHT, the more the risk increased – but these duration associations were weaker for the oestrogen-only and tibolone preparations. Importantly, this research did not confirm the higher-than-expected breast cancer risks reported from a major meta-analysis (Collaborative Group on Hormonal Factors in Breast Cancer, 2019).

Women, especially those with an elevated risk of any side effect, should have informed discussions with their doctors about the most appropriate treatment.

This research did not confirm the higher-than-expected breast cancer risks reported from a 2019 meta-analysis.